Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TMS Co's book value per share for the quarter that ended in Dec. 2025 was 円60.92.
During the past 12 months, TMS Co's average Book Value Per Share Growth Rate was -18.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 1.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of TMS Co was 40.60% per year. The lowest was 1.30% per year. And the median was 20.95% per year.
TMS Co's current price is 円98.00. Its book value per share for the quarter that ended in Dec. 2025 was 円60.92. Hence, today's PB Ratio of TMS Co is 1.61.
During the past 5 years, the highest P/B Ratio of TMS Co was 1.60. The lowest was 0.00. And the median was 0.00.
TMS Co (TSE:4891) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
TMS Co Book Value per Share Related Terms
TMS Co Book Value per Share Historical Data
* Premium members only.
The historical data trend for TMS Co's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4891 vs VRTX, REGN, RVMD: Book Value per Share Comparison
For the Biotechnology subindustry, TMS Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TMS Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TMS Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where TMS Co's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TMS Co (TSE:4891) has a Book Value per Share of 円60.92 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on TMS Co and its competitors.
Is TMS Co's Book Value per Share too high?
TMS Co's current Book Value per Share is 円60.92. Overall, TMS Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's Book Value per Share compare to VRTX and REGN?
TMS Co's Book Value per Share of 円60.92 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on TMS Co and its competitors. TMS Co's current Book Value per Share is 円60.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current Book Value per Share of 円60.92. The current Book Value per Share is 円60.92. TMS Co's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For TMS Co (TSE:4891), the current Book Value per Share is 円60.92 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score
Get the complete analysis for TSE:4891
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4891 has been successfully added to your 
